← All countries · Americas
93%
MCV1
2025 · WHO/UNICEF estimate
95%
DTP3
2025 · WHO/UNICEF estimate
95%
IPV complete
2025 · WHO/UNICEF estimate
95%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 98%2025 · WHO/UNICEF estimate | 98.4% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 95%2025 · WHO/UNICEF estimate | 94.1% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 95%2025 · WHO/UNICEF estimate | 95.4% | B · good | |
| IPV1First dose of inactivated polio vaccine | 95%2025 · WHO/UNICEF estimate | 93.9% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 95%2025 · WHO/UNICEF estimate | 94.5% | C · weak | |
| MCV1First dose of measles-containing vaccine | 93%2025 · WHO/UNICEF estimate | 93.3% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 93%2025 · WHO/UNICEF estimate | 92.9% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 93%2025 · WHO/UNICEF estimate | 93.3% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 95%2025 · WHO/UNICEF estimate | 95.5% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | 55%2025 · WHO/UNICEF estimate | 55.2% | C · weak | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 95%2025 · WHO/UNICEF estimate | 95.2% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 84.8%2021 · Administrative (country-reported) | 84.8% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 44.6%2021 · Administrative (country-reported) | 44.6% | D · poor | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 93%2024 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 30%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 30%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 19%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 12025 | 0.4per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 42025 | 1.4per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02007 | 0per 1,000,000 total population | no data | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (63 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | Birth cohort |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents chronic conditions, adults chronic conditions, older adults chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | W6 | Risk group(s) | Children <7Y with pertussis contraindication |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M3 | Risk group(s) | Children <7Y with pertussis contraindication |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | M6 | Risk group(s) | Children <7Y with pertussis contraindication |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 4 | M18 | Risk group(s) | Children <7Y with pertussis contraindication |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y4-Y6 | Risk group(s) | Children <7Y with pertussis contraindication |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | Children <7 yrs |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4-Y6 | General/routine | Children <7 yrs |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | W6 | General/routine | Routine |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M3 | General/routine | Routine |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | Routine |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | HCWs, contacts of HepB positive cases, post-exposure prophylaxis |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | HCWs, contacts of HepB positive cases, post-exposure prophylaxis |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +W4 | Health workers | HCWs, contacts of HepB positive cases, post-exposure prophylaxis |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +W4 | Risk group(s) | HCWs, contacts of HepB positive cases, post-exposure prophylaxis |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | HCWs, contacts of HepB positive cases, post-exposure prophylaxis |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | HCWs, contacts of HepB positive cases, post-exposure prophylaxis |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Birth cohort - Less than 24 hours |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | W6 | Risk group(s) | Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M3 | Risk group(s) | Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | Risk group(s) | Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | W6 | Risk group(s) | children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M3 | Risk group(s) | children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis |
| HIBHib (Haemophilus influenzae type B) vaccine | 3 | M6 | Risk group(s) | children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11-Y12 | HPV administered to females and males | Females 9-26 years, Males 9-14 years (Main target is secondary school entry (grade 7) which is children Y11-12). One dose is administered to persons between the ages 9 to 14 years old, 2 doses are administered to persons between the ages 15 to 26 years old, and 3 doses are administered to immunocompromised persons regardless of age. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | 1st contact | Risk group(s) | Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6 |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M1 | Risk group(s) | Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6 |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 3 | +M6 | Risk group(s) | Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6 |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M35 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | W6 | General/routine | Routine |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | Routine |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Routine |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | Routine |
| OPVOPV (Oral polio vaccine) | 2 | M3 | General/routine | Routine |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | Routine |
| OPVOPV (Oral polio vaccine) | 5 | Y4-Y6 | General/routine | Routine |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | W6 | Risk group(s) | Persons with Downs Syndrome, Sickle Cell Disease, HIV and Rheumatic Fever |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M3 | Risk group(s) | Persons with Downs Syndrome, Sickle Cell Disease, HIV and Rheumatic Fever |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | Risk group(s) | Persons with Downs Syndrome, Sickle Cell Disease, HIV and Rheumatic Fever |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M15 | Risk group(s) | Persons with Downs Syndrome, Sickle Cell Disease, HIV and Rheumatic Fever |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Y4 | Risk group(s) | Persons with Sickle Cell Disease |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Adults | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Adults | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Adults | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Adults | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | pregnant women and adults, 10 year booster given to risk groups |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y11-Y12 | General/routine | Routine |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | +Y10 | Risk group(s) | pregnant women and adults, 10 year booster given to risk groups |
| YFYF (Yellow fever) vaccine | 1 | >M12 | Travellers | Travellers to endemic countries |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.